title: Incorporating molecular tools into early-stage clinical trials.
authors.affiliation: Brain Tumor and Neuro-Oncology Center, Department of Neurosurgery and the Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States of America. weilr@ccf.org
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Weil
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000601:surgery; D002986:Clinical Trials as Topic / Q000379:methods*; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005909:Glioblastoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000601:surgery; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000601:surgery; D051059:PTEN Phosphohydrolase / Q000172:deficiency / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; C512478:EGFR protein, human; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D020123:Sirolimus